ElpasBio Completes Patient Enrollment in Phase III Trial of AlloJoin for Knee Osteoarthritis
This marks the first stem cell therapy for KOA to reach Phase III in China. The race is heating up...
Key Points
- ElpasBio has completed patient enrollment in its China Phase III pivotal trial of AlloJoin® for knee osteoarthritis, with more than 500 patients enrolled.
- AlloJoin® is an allogeneic (donor derived) human adipose-derived mesenchymal stem cell (haMPC) therapy being studied as an off-the-shelf treatment for knee osteoarthritis.
- ElpasBio plans a Phase III data readout in 2027 and says it will work with Fosun Kairos on commercialization in Mainland China, Hong Kong SAR, and Macau SAR.
The KOA Race Heating Up…
ElpasBio, a Chinese biotech company, says it completed patient enrollment in its Chinese Phase III trial for AlloJoin® (lotazadromcel), a cell therapy for knee osteoarthritis, in May. It’s difficult to find information on the therapy or company, but for context, AlloJoin® is an allogeneic (donor-derived) human adipose-derived mesenchymal stem cell (haMPC) therapy.
The Phase III reportedly enrolled over 500 patients; data readout is planned for 2027, and they plan to submit a New Drug Application to China’s Center for Drug Evaluation later in the year. ElpasBio also mentioned that AlloJoin® is the first stem cell drug in China to enter Phase III for knee osteoarthritis.
AlloJoin’s trial is studying its ability to:
- Reduce inflammation
- Promote repair of damaged cartilage
- Provide durable symptom relief
- Potentially modify disease progression
This comes about 6 months after the company announced a partnership with Fosun Kairos, a Chinese CDMO, to manufacture AlloJoin.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
